Skip Navigation

AIDSInfo-at-a-glance

Issue No. 53 | December 09, 2011
A Service of the U.S. Department of Health and Human ServicesView HTML version
News and Features 

FDA Updates Ritonavir (Norvir) Label with New Safety Information

“On December 7, 2011, the Food and Drug Administration approved the following revisions to the Norvir (ritonavir) tablets, capsules and oral solution product labeling:

“The Contraindications section was updated to include toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome.
 
“The Warning and Precautions, Adverse Reactions and Postmarketing Experience sections were updated to include toxic epidermal necrolysis (TEN) …
 
Section 7: Drug Interaction was updated to include information regarding the anticancer agents dasatinib and nilotinib and fentanyl.”
 
The updated label will be available at the FDA Web site.
 
More information is available:

2010 NIAID Year in Review Includes Summary of HIV/AIDS Research Accomplishments

The National Institute of Allergy and Infectious Diseases (NIAID) recently posted the 2010 NIAID Year in Review on the NIAID Web site. The review describes the Institute’s scientific and programmatic accomplishments in FY 2010 and provides information on the budget for NIAID-supported initiatives and programs.

NIAID HIV/AIDS research activities detailed in the review include the following:

  • New Directions in HIV Prevention: Description of NIAID-sponsored research aimed at preventing HIV infection, including approaches such as pre-exposure prophylaxis (PrEP), vaccines, and microbicides.
  • Recent Successes in Developing an HIV Vaccine: Summaries of scientific findings resulting from NIAID-supported research into the development of an HIV vaccine.
  • Reducing the Impact of HIV: Information about NIAID’s support for research on eliminating persistent HIV viral reservoirs and extending PrEP research and on a NIAID initiative to respond to the HIV/AIDS epidemic in Washington DC.
  • Reducing the Transmission of HIV: Summary of results from the iPrEx study showing that a daily dose of emtricitabine and tenofovir (Truvada) reduced the risk of HIV acquisition among men who have sex with men (MSM).

CDC Updates “HIV among Youth” Fact Sheet

The Centers for Disease Control and Prevention (CDC) recently updated the “HIV among Youth” fact sheet. This fact sheet provides information and statistics on diagnoses of HIV infection and AIDS in people 13 to 29 years old. Prevention challenges in this population, including sexual risk factors, substance use, and a lack of awareness are detailed. The fact sheet also includes information on CDC programs and research that focuses on reducing the risk of HIV infection among young people.

Home | Guidelines | Clinical Trials | Drugs | Health Topics | Education Materials | Mobile Resources & Tools
Unsubscribe | Contact Us
Left footer corner image Left footer corner image